Author:
Olivier Magali,Hainaut Pierre,Børresen-Dale Anne-Lise
Reference76 articles.
1. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE. 1996. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811-814.
2. Ahrendt SA, Halachmi S, Chow JT, Wu L, Halachmi N, Yang SC, Wehage S, Jen J, Sidransky D. 1999. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci U S A 96:7382-7387.
3. Ahrendt SA, Hu Y, Buta M, McDermott MP, Benoit N, Yang SC, Wu L, Sidransky D. 2003. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst 95:961-970.
4. Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J. 2000. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 6:3923-3931.
5. Aurelio ON, Kong XT, Gupta S, Stanbridge EJ. 2000. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. Mol Cell Biol 20:770-778.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献